Peter Mohr - Researcher Profile | RDL Research Database

Publications

3 shown

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial

Jeffrey S. Weber , Sandra P. D’Angelo , David R. Minor +25 more

2015 The Lancet Oncology 2617 citations

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

Georgina V. Long , Daniil Stroyakovskiy , Helen Gogas +32 more

A combination of dabrafenib and trametinib, as compared with dabrafenib alone, improved the rate of progression-free survival in previously untreated patients who had metastatic...

2014 New England Journal of Medicine 1791 citations

Fotemustine Compared With Dacarbazine in Patients With Disseminated Malignant Melanoma: A Phase III Study

Marie‐Françoise Avril , Steinar Aamdal , Jean‐Jacques Grob +17 more

Purpose To compare fotemustine and dacarbazine (DTIC) in terms of overall response rate (ORR) as primary end-point and overall survival, duration of responses, time to progressi...

2004 Journal of Clinical Oncology 469 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 4,877
Institution: Elbe Kliniken Stade-Buxtehude

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-7328-7407

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.